title: Safety of 12 core transrectal ultrasound guided prostate biopsy in patients on aspirin.
abstract: OBJECTIVE
  To prospectively assess safety outcome of TRUS guided prostate biopsy in patients taking low dose aspirin.
  
  
  METHODS
  Consecutive patients, who were planned for 12 core TRUS guided prostate biopsy and satisfied eligibility criteria, were included in the study and divided into two Groups: Group A: patients on aspirin during biopsy, Group B: patients not on aspirin during biopsy, including patients in whom aspirin was stopped prior to the biopsy. Parameters included for statistical analysis were: age, serum prostate specific antigen (PSA), prostate volume, hemoglobin (Hb %), number of hematuria episodes, number of patient reporting hematuria, hematuria requiring intervention, number of patient reporting hematospermia and number of patient reporting rectal bleeding.
  
  
  RESULTS
  Of 681 eligible patients, Group A and B had 191 and 490 patients respectively. The mean age, prostate volume, serum PSA and pre-biopsy hemoglobin were similar in both Groups with no significant differences noted between them. None of the post-biopsy complications, including number of hematuria episodes (p=0.83), number of patients reporting hematuria (p=0.55), number of patients reporting hematospermia (p=0.36) and number of patients reporting rectal bleeding (p=0.65), were significantly different between Groups A and B respectively. None of the hemorrhagic complication in either group required intervention and were self limiting.
  
  
  CONCLUSIONS
  Continuing low dose aspirin during TRUS guided prostate biopsy neither alters the minor bleeding episodes nor causes major bleeding complication. So, discontinuation of low dose aspirin prior to TRUS guided prostate biopsy is not required.
authors.affiliation: Department of Urology, V.M. Medical College and Safdarjang Hospital, New Delhi 110029, India.
authors.forename: Pawan
authors.initials: P
authors.lastname: Vasudeva
authors.affiliation: Department of Urology, V.M. Medical College and Safdarjang Hospital, New Delhi 110029, India.
authors.forename: Niraj
authors.initials: N
authors.lastname: Kumar
authors.affiliation: Department of Urology, V.M. Medical College and Safdarjang Hospital, New Delhi 110029, India.
authors.forename: Anup
authors.initials: A
authors.lastname: Kumar
authors.affiliation: Department of Urology, V.M. Medical College and Safdarjang Hospital, New Delhi 110029, India.
authors.forename: Harbinder
authors.initials: H
authors.lastname: Singh
authors.affiliation: Department of Urology, V.M. Medical College and Safdarjang Hospital, New Delhi 110029, India.
authors.forename: Gaurav
authors.initials: G
authors.lastname: Kumar
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D062005:Biopsy, Large-Core Needle / Q000009:adverse effects / Q000379:methods*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D010976:Platelet Count; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology; D012007:Rectum / Q000000981:diagnostic imaging; D015203:Reproducibility of Results; D012307:Risk Factors; D018084:Ultrasonography, Interventional / Q000009:adverse effects / Q000379:methods*
chemical_list: D010975:Platelet Aggregation Inhibitors; D017430:Prostate-Specific Antigen; D001241:Aspirin